环氧化酶抑制与心血管风险。 - Suppr

Suppr

超能文献

Cyclooxygenase inhibition and cardiovascular risk.

作者信息

Antman Elliott M, DeMets David, Loscalzo Joseph

机构信息

Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115, USA.

出版信息

Circulation. 2005 Aug 2;112(5):759-70. doi: 10.1161/CIRCULATIONAHA.105.568451.

DOI:10.1161/CIRCULATIONAHA.105.568451

PMID:16061757

Abstract

摘要

相似文献

Cyclooxygenase inhibition and cardiovascular risk.

Circulation. 2005 Aug 2;112(5):759-70. doi: 10.1161/CIRCULATIONAHA.105.568451.

COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?

Expert Opin Drug Saf. 2006 Jan;5(1):1-2; author reply 1-2. doi: 10.1517/14740338.5.1.1.

The Vioxx debacle revisited.

Am J Med. 2005 Sep;118(9):1056-7; author reply 1057. doi: 10.1016/j.amjmed.2005.04.024.

Valdecoxib: cutaneous and vascular risks.

Prescrire Int. 2005 Apr;14(76):63.

Celecoxib and cardiovascular risks.

Expert Opin Drug Saf. 2005 Nov;4(6):1005-15. doi: 10.1517/14740338.4.6.1005.

[Overestimated].

Med Klin (Munich). 2006 Aug 15;101(8):676-7; author reply 678-9.

Celecoxib shown effective in preventing colon polyps.

J Natl Cancer Inst. 2006 May 17;98(10):665-7. doi: 10.1093/jnci/djj220.

Does celecoxib use increase the risk of cardiovascular events?

Gastroenterology. 2005 Oct;129(4):1348-50. doi: 10.1053/j.gastro.2005.08.029.

COX-2 inhibitors and the heart: putting risk in perspective.

Adv Nurse Pract. 2005 Nov;13(11):48-50.

Precaution, cyclooxygenase inhibition, and cardiovascular risk.

Trends Pharmacol Sci. 2009 Oct;30(10):503-8. doi: 10.1016/j.tips.2009.07.007. Epub 2009 Sep 15.

引用本文的文献

Genetic Evidence for Causal Relationships between Plasma Eicosanoid Levels and Cardiovascular Disease.

Metabolites. 2024 May 23;14(6):294. doi: 10.3390/metabo14060294.

Myeloid Cell mPGES-1 Deletion Attenuates Calcium Phosphate-induced Abdominal Aortic Aneurysm in Male Mice.

Inflammation. 2025 Feb;48(1):288-298. doi: 10.1007/s10753-024-02055-w. Epub 2024 Jun 12.

Role of cyclooxygenases 1 and 2 in the maintenance of colonic mucosal integrity in an experimental colitis model.

Braz J Med Biol Res. 2023 Oct 27;56:e12946. doi: 10.1590/1414-431X2023e12946. eCollection 2023.

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System.

J Clin Med. 2023 Sep 20;12(18):6089. doi: 10.3390/jcm12186089.

Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis.

BMC Musculoskelet Disord. 2023 May 18;24(1):394. doi: 10.1186/s12891-023-06488-6.

Natural product-driven dual COX-LOX inhibitors: Overview of recent studies on the development of novel anti-inflammatory agents.

Heliyon. 2023 Mar 14;9(3):e14569. doi: 10.1016/j.heliyon.2023.e14569. eCollection 2023 Mar.

Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.

Biomedicines. 2023 Jan 25;11(2):338. doi: 10.3390/biomedicines11020338.

New Insights Into the Pharmacological Management of Postoperative Pain: A Narrative Review.

Cureus. 2022 Mar 10;14(3):e23037. doi: 10.7759/cureus.23037. eCollection 2022 Mar.

Impact of age and cyclooxygenase inhibition on the hemodynamic response to acute cognitive challenges.

Am J Physiol Regul Integr Comp Physiol. 2021 Aug 1;321(2):R208-R219. doi: 10.1152/ajpregu.00048.2021. Epub 2021 Jun 23.

Prevalence of Gastrointestinal and Cardiovascular Risk in Patients with Degenerative Lumbar Spinal Disease.

Clin Orthop Surg. 2020 Sep;12(3):343-352. doi: 10.4055/cios20021. Epub 2020 Aug 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Cyclooxygenase inhibition and cardiovascular risk.

Circulation. 2005 Aug 2;112(5):759-70. doi: 10.1161/CIRCULATIONAHA.105.568451.

COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?

Expert Opin Drug Saf. 2006 Jan;5(1):1-2; author reply 1-2. doi: 10.1517/14740338.5.1.1.

The Vioxx debacle revisited.

Am J Med. 2005 Sep;118(9):1056-7; author reply 1057. doi: 10.1016/j.amjmed.2005.04.024.

Valdecoxib: cutaneous and vascular risks.

Prescrire Int. 2005 Apr;14(76):63.

Celecoxib and cardiovascular risks.

Expert Opin Drug Saf. 2005 Nov;4(6):1005-15. doi: 10.1517/14740338.4.6.1005.

[Overestimated].

Med Klin (Munich). 2006 Aug 15;101(8):676-7; author reply 678-9.

Celecoxib shown effective in preventing colon polyps.

J Natl Cancer Inst. 2006 May 17;98(10):665-7. doi: 10.1093/jnci/djj220.

Does celecoxib use increase the risk of cardiovascular events?

Gastroenterology. 2005 Oct;129(4):1348-50. doi: 10.1053/j.gastro.2005.08.029.

COX-2 inhibitors and the heart: putting risk in perspective.

Adv Nurse Pract. 2005 Nov;13(11):48-50.

Precaution, cyclooxygenase inhibition, and cardiovascular risk.

Trends Pharmacol Sci. 2009 Oct;30(10):503-8. doi: 10.1016/j.tips.2009.07.007. Epub 2009 Sep 15.

引用本文的文献

Genetic Evidence for Causal Relationships between Plasma Eicosanoid Levels and Cardiovascular Disease.

Metabolites. 2024 May 23;14(6):294. doi: 10.3390/metabo14060294.

Myeloid Cell mPGES-1 Deletion Attenuates Calcium Phosphate-induced Abdominal Aortic Aneurysm in Male Mice.

Inflammation. 2025 Feb;48(1):288-298. doi: 10.1007/s10753-024-02055-w. Epub 2024 Jun 12.

Role of cyclooxygenases 1 and 2 in the maintenance of colonic mucosal integrity in an experimental colitis model.

Braz J Med Biol Res. 2023 Oct 27;56:e12946. doi: 10.1590/1414-431X2023e12946. eCollection 2023.

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System.

J Clin Med. 2023 Sep 20;12(18):6089. doi: 10.3390/jcm12186089.

Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis.

BMC Musculoskelet Disord. 2023 May 18;24(1):394. doi: 10.1186/s12891-023-06488-6.

Natural product-driven dual COX-LOX inhibitors: Overview of recent studies on the development of novel anti-inflammatory agents.

Heliyon. 2023 Mar 14;9(3):e14569. doi: 10.1016/j.heliyon.2023.e14569. eCollection 2023 Mar.

Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.

Biomedicines. 2023 Jan 25;11(2):338. doi: 10.3390/biomedicines11020338.

New Insights Into the Pharmacological Management of Postoperative Pain: A Narrative Review.

Cureus. 2022 Mar 10;14(3):e23037. doi: 10.7759/cureus.23037. eCollection 2022 Mar.

Impact of age and cyclooxygenase inhibition on the hemodynamic response to acute cognitive challenges.

Am J Physiol Regul Integr Comp Physiol. 2021 Aug 1;321(2):R208-R219. doi: 10.1152/ajpregu.00048.2021. Epub 2021 Jun 23.

Prevalence of Gastrointestinal and Cardiovascular Risk in Patients with Degenerative Lumbar Spinal Disease.

Clin Orthop Surg. 2020 Sep;12(3):343-352. doi: 10.4055/cios20021. Epub 2020 Aug 19.